An Open-Label Multicenter Phase 1a Study of AN2025 and AN0025 in Double Combination with Atezolizumab and in Triple Combination with Atezolizumab in Patients with Advanced Solid Tumors.

Brief description of study

You can participate in this study if you are diagnosed with advanced solid tumors. The purpose of this study is to assess the Safety, Tolerability, and Efficacy of the study drug (AN2025) individually, and in Combination with the study drug (Atezolizumab) in subjects with advanced solid tumors. The study is also being done to learn more about how the study drugs are absorbed (taken up in the body), metabolized (broken down by the body), distributed (circulated in the body), and eliminated (passed out of the body). The patients will be monitored and taken care of while on these medication during the entire study period.


Clinical Study Identifier: s22-00432
Principal Investigator: Kristen Spencer.
Other Investigators: Nila Theresa De La Rosa, Nina Beri, Jessica Wang, Eneil De La Pena, Salman Rafi Punekar, Elaine Shum, Jeffrey S. Weber, Samantha VanMaanen, Scot Niglio, Keriann M Scavone, Vamsidhar Velcheti, Joshua K Sabari, Kathleen M Madden, Caitlin Elizabeth Ryan, Douglas K Marks, Janice Mehnert, David R. Wise.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.